Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Icapamespib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Samus will proceed with its Phase 1b study addressing the safety, tolerability and pharmacokinetics of PU-AD (icapamespib) in patients with recurrent malignant glioma. Icapamespib is an orally administered small molecule that is a specific inhibitor of e...
Product Name : PU-AD
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2021
Lead Product(s) : Icapamespib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Icapamespib
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase 1 study results presented today support Samus’ advancement of PU-AD into its now initiated Phase 2a study in AD, and its upcoming Phase 2a study in ALS expected to initiate later this year.
Product Name : PU-AD
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 29, 2020
Lead Product(s) : Icapamespib
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable